Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Esketamine ...

and a safety follow-up through 2 weeks after the last dose of trial treatment (Fig. S1). After the screening phase, patients were randomly assigned, in a 1:1 ratio, to receive esketamine nasal ...

The FDA said this is the first time esketamine was approved for any use ... be monitored for "at least two hours" after receiving a dose and can't drive for the rest of the day.

You won’t drive or do other tasks that require an alert mind on the day of your dose. No, Spravato is not the same drug as ketamine. The active ingredient in Spravato is esketamine. There is ...

More information: Efficacy of a single low dose of esketamine after childbirth for mothers with symptoms of prenatal depression: randomised clinical trial, The BMJ (2024). DOI: 10.1136/bmj-2023-078218 ...

One low dose injection of esketamine administered right after childbirth reduces major depressive episodes in those with prenatal depression, according to a new study. When considering ketamine ...

for SPRAVATO ® (esketamine) CIII nasal spray, making this innovative treatment the first and only monotherapy for adults living with major depressive disorder (MDD) who have had an inadequate ...

The FDA approved esketamine (Spravato) nasal spray as monotherapy for adults with treatment-resistant depression who had an ...

It compared nasal esketamine to only one other drug. Other drugs used to augment treatment in patients with treatment-resistant depression include low-dose lithium, thyroid medication, atypical ...